Go to content
UR Home

Members of Regensburg Center Of Neuroscience

Sabine Amslinger

Thomas Baghai, Clinical Neurosciences

Prof. Dr. Thomas C. Baghai, Dept. of Psychiatry and Psychotherapy, University of Regensburg

+++under construction+++



Anton Beer

Ulrich Bogdahn, Neurology

Prof. Dr. Ulrich Bogdahn, Klinik für Neurologie der Universität Regensburg am Bezirksklinikum

The group is concentrating on biomarker development and new treatments for neurodegenerative disorders, hereby focusing on ALS (amyotrophic lateral sclerosis). The group tries to use clinical available biomarkers from neurophysiology and neuroimaging as well as hematological parameters from stem cell biology to validate future biomarkers for clinical trials in this disease category. Also a new drug is being developed within the framework of the BMBF GO-Bio initiative; here the aim is clearly to stimulate compensatory neurogenesis in patients with neurodegenerative disorders. The compound being looked at is a cytokine signaling antagonist that will functionally restore neurogenic proliferation. The group is also a member of the German BMBF funded motoneuron network MND-Network coordinated by the University of Ulm. In addition we are also a member of the NISALS consortium, which tries to standardize neuro imaging procedures in ALS.
Intense cooperations with the Departments of Hematooncology, UKR; Institute of Neuropathology, UKR; Institute and clinics for Radiology and Neuroradiology, UKR/BKR; Institute of Microbiology, UKR



Oliver Bosch, Neurobiology and Animal Physiology

Prof. Dr. Oliver Bosch, Maternal Group, Lehrstuhl für Neurobiologie and Tierphysiologie, Universität Regensburg

Positive social relationships are beneficial for both physiological and psychological well-being. Here, the brain neuropeptides vasopressin and oxytocin as well as CRF and the urocortins have great impact. We study how these neuropeptides (dys-)regulate mother-pup bonding, the first bond mammals experience in their lifes. In addition, we are interested in the short- and long-term effects of breaking a male-female pair bond from the cellular to the behavioural level.



Alexander Brawanski, Neurosurgery

Prof. Dr. Alexander Brawanski, Klinik und Poliklinik für Neurochirungie, Universitätsklinikum Regensburg

Despite the improvement of surgical techniques, a number of diseases requiring neurosurgical management still show unsatisfying outcome. This is cardinally because the pathogenesis of these conditions is incompletely understood. Our research therefore focusses on the molecular basis of clinically relevant mechanisms in order to improve treatment outcome. We currently have segregated our projects in four main areas of research: 1. Subarachoid hemorrhage related vasospasm: The role of vasoactive peptides is evaluated using ELISA, Western blot and immunohistochemistry in correlation to clinical presentation and outcome (Fig. 1). 2. Neuro – Imaging: The main focus is on the preoperative segmentation of preoperative MRI imaging in patients with brain tumors. The ultimate goal is to define the most adequate surgical trajectory in order to achieve maximal tumor resection with minimal surgical toxicity (Fig.2). 3. Deep brain stimulation: This team employs advanced imaging modalities such as diffusion tensor imaging and tractography in order to optimize the position of deep brain stimulation electrodes (Fig.3). 4. Brain tumor biology: This more basic research oriented group focusses on the specific metabolism of malignant brain tumors with regard to pH regulation and cell survival (Fig.4). In addition, the mechanisms of bone invasion are analyzed using co-culture techniques, gene knockdown approaches and in vitro functional assays (Fig. 5).

Fig. 1: CT scan of a patient with subarachnoid hemorrhage; corresponding angiogram with severe vasospasm critically reducing the cerebral blood supply; immunofluorescence staining of Neuropeptide Y expressed by smooth muscle fibers of a brain micovessel (from: Molecular, cellular and developmental biology (www.yale.edu))

Fig. 2: Preoperative segmentation of a primary malignant brain tumor.

Fig. 3: Target planning for a deep brain stimulation procedure in a patient with Parkinson's disease. DTI imaging based fiber tracking highlights the internal capsule.

Fig. 4: Carboanhydrase IX expression in primary brain tumors increases with grade of malignancy

Fig. 5: Tumor – bone chip co-culture assay reveals extensive meningioma cell infiltration